U.S. Pharma Stock News

NYSE:NEXA
NYSE:NEXAMetals and Mining

Is It Too Late To Consider Nexa Resources (NEXA) After Its 113% One-Year Surge?

If you are wondering whether Nexa Resources at around US$10.95 is still offering value after its recent run, you are not alone. This article will focus on what the current price might imply. The stock has returned 0.7% over the last 7 days and 24.6% year to date, with a 112.9% return over the past year, even though the 30 day return sits at an 11.6% decline. Recent news flow around Nexa Resources has centered on broader sector sentiment, funding conditions and company-specific operational...
NYSE:CTOS
NYSE:CTOSTrade Distributors

Why Custom Truck One Source (CTOS) Is Down 8.7% After Mixed Q4 Results And 2026 Outlook Shift

In March 2026, Custom Truck One Source reported mixed fourth-quarter and full-year 2025 results, with record quarterly revenue of US$528.18 million and full-year revenue of US$1.94 billion but a wider annual net loss of US$31.05 million, while earnings per share in the quarter beat market expectations despite a revenue miss. Management highlighted record rental fleet utilization near 84%, new OEM partnerships, and 2026 guidance calling for 3% to 9% revenue growth and higher adjusted EBITDA,...
NYSE:IOT
NYSE:IOTSoftware

Is It Time To Reassess Samsara (IOT) After Recent Share Price Pullback?

If you are looking at Samsara and wondering whether the current share price lines up with the underlying business, this article will walk through what the numbers suggest about value. The stock last closed at US$31.72, with returns of a 10.3% decline over the past week, 14.3% over the past month, a 6.5% decline year to date and a 16.7% decline over the past year, while the 3-year return sits at 66.8%. Recent coverage around Samsara has focused on its position in connected operations software...
NasdaqGS:RELY
NasdaqGS:RELYDiversified Financial

Remitly CEO Shift And 2026 AI Plan Weighed Against Valuation

Remitly Global (NasdaqGS:RELY) has announced a CEO transition, appointing Sebastian Gunningham to lead the company. The move comes as Remitly reports its first full year of GAAP profitability. Management has outlined a 2026 plan focused on AI driven product development and broader geographic expansion. The company is also targeting growth in new product revenue and plans to increase share repurchases in the coming year. For investors watching Remitly Global at a share price of $15.25, the...
NasdaqGS:CFLT
NasdaqGS:CFLTSoftware

Confluent FedRAMP Approval Opens New Government Real Time Data Prospects

Confluent secured FedRAMP Moderate Authorization for its cloud data streaming platform, Confluent Cloud for Government. The authorization enables US government agencies to use Confluent's managed service for mission critical, real time data streaming workloads. This approval opens access to a new segment of federal and other regulated customers that require FedRAMP certified cloud services. For investors watching Confluent (NasdaqGS:CFLT), the FedRAMP Moderate Authorization adds a new angle...
NYSE:RLX
NYSE:RLXTobacco

RLX Technology NYSE RLX Margin Compression Tests Bullish Turnaround Narrative

RLX Technology (NYSE:RLX) has put fresh numbers on the table, with third quarter FY 2025 revenue at C¥1.03b and basic EPS of C¥0.17, set against a trailing twelve month basic EPS of C¥0.63 on revenue of C¥3.27b. The company has seen revenue move from C¥736.21m in Q4 2024 to C¥794.12m in Q2 2025 and then to C¥1.03b in Q3 2025. Quarterly basic EPS shifted from C¥0.10 in Q4 2024 to C¥0.18 in Q1 2025 before landing at C¥0.17 most recently, giving investors fresh data points on how headline growth...
NasdaqGS:IPGP
NasdaqGS:IPGPElectronic

Is It Too Late To Consider IPG Photonics (IPGP) After Its 78% One-Year Surge?

If you are asking whether IPG Photonics at around US$110.95 still offers value after its recent run, this article will walk through what the current price may or may not be reflecting. The stock has been volatile recently, with a 7 day return of an 8.1% decline, flat performance over 30 days, but a 48.2% return year to date and 78.2% over the past year. The 3 year and 5 year returns sit at a 4.6% decline and a 47.6% decline respectively. Recent coverage of IPG Photonics has focused on its...
NYSE:ARW
NYSE:ARWElectronic

Arrow Electronics’ Infineon And Microsoft Wins Reframe Growth And Valuation Story

Arrow Electronics (NYSE:ARW) has partnered with Infineon Technologies on a new 240W USB-C power reference design for motor control systems. The company has also been named Microsoft's 2025 Distributor Partner of the Year for its ArrowSphere AI offerings. Arrow Electronics, trading at $140.44, has seen its shares move 1.5% over the past week and 24.2% year to date, with a 34.1% return over the past year. In that context, the Infineon collaboration and the Microsoft award give investors...
NasdaqGS:OZK
NasdaqGS:OZKBanks

Is It Time To Revisit Bank OZK (OZK) After The Recent Share Price Pullback?

If you are wondering whether Bank OZK is offering good value at its recent price, this article walks through what the numbers say about where the stock stands today. The share price recently closed at US$43.40, with returns of 2.1% over 1 year, 36.4% over 3 years and 18.3% over 5 years. The stock has seen a 3.7% decline over 7 days and an 11.9% decline over 30 days, contributing to a 7.7% decline year to date. Recent coverage of regional banks has kept investor attention on how balance...
NasdaqGS:JCAP
NasdaqGS:JCAPConsumer Finance

Jefferson Capital (JCAP) Margin Strength Reinforces Bullish Narratives Despite Softer Growth Outlook

Jefferson Capital (JCAP) closed out FY 2025 with fourth quarter revenue of US$154.8 million and net income of US$37.7 million, translating to basic EPS of US$0.65 on a reported basis. The company has seen quarterly revenue move from US$118.9 million in Q4 2024 to US$154.8 million in Q4 2025, while trailing twelve month net income reached US$188.0 million and EPS came in at US$6.26. This sets the stage for investors to focus on how sustainable these earnings and margins might be. With net...
NasdaqGS:INMD
NasdaqGS:INMDMedical Equipment

InMode (INMD) Valuation Check As New US$ Share Buyback Targets Around 10% Of Outstanding Stock

InMode (INMD) has introduced a new US$ share repurchase program, authorizing the buyback of up to 6,380,000 shares, or about 10% of its outstanding stock, using available cash. See our latest analysis for InMode. The buyback news comes after a mixed stretch for investors, with a 1-day share price return of 6.11% and a 7-day share price return of 2.34% contrasting with a year-to-date share price return decline of 8.51% and a 1-year total shareholder return decline of 26.05%. This suggests that...
NasdaqGS:AEVA
NasdaqGS:AEVAElectronic

Reassessing Aeva Technologies (AEVA) Valuation After A Very Large One Year Share Price Jump

If you are wondering whether Aeva Technologies' current share price lines up with its real value, you are not alone. This article is here to unpack that question step by step. The stock last closed at US$15.16, with returns of 7.0% over 7 days, 19.0% over 30 days, 18.9% year to date, a very large 1 year return that sits well above 400%, a 3 year return of 84.9%, and a 5 year return of a 79.2% decline. These moves have put Aeva back on many watchlists, as investors reassess how the market is...
NYSE:KOF
NYSE:KOFBeverage

Is It Time To Revisit Coca-Cola FEMSA (NYSE:KOF) After The Recent Share Price Pullback?

If you are wondering whether Coca-Cola FEMSA. de is still offering fair value at around US$97.16 per share, this article will walk through what the current price might be implying about the business. The stock has seen mixed recent returns, with a 6.8% decline over the past week and a 13.7% decline over the last month, set against longer term returns of 2.4% year to date, 13.6% over 1 year, 45.3% over 3 years and 154.2% over 5 years. Recent attention around Coca-Cola FEMSA. de has centered...
NasdaqGS:DYN
NasdaqGS:DYNBiotechs

Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case

Dyne Therapeutics plans to submit an accelerated application for its Duchenne muscular dystrophy drug, targeting a potential commercial launch in early 2027. The company has completed enrollment in its Phase 1/2 trial in myotonic dystrophy type 1 and started a Phase 3 trial for DYNE-101 in DM1. New long term DELIVER trial data report meaningful improvements in lung and cardiac function in patients with Duchenne muscular dystrophy. For investors watching NasdaqGS:DYN, these clinical and...
NYSE:SBH
NYSE:SBHSpecialty Retail

Is It Time To Revisit Sally Beauty Holdings (SBH) After Its 59% One-Year Share Price Jump?

If you are wondering whether Sally Beauty Holdings is still worth your attention at around US$14.54 per share, this article walks through what that price could mean for value focused investors. The stock is roughly flat year to date with a 0.3% return. However, the 59.4% return over the past year, alongside shorter term moves of a 1.7% decline over 7 days and a 4.5% decline over 30 days, suggests sentiment has shifted more than once recently. Recent coverage has focused on Sally Beauty...
NasdaqGS:LSTR
NasdaqGS:LSTRTransportation

How Landstar’s Heavy Haul and Mexico Expansion Amid Softer Freight Demand Will Impact Landstar System (LSTR) Investors

In recent updates, Landstar System expanded its heavy haul and Mexico cross-border services while maintaining dividends, share repurchases, and a lower long-term debt load. This combination of operational expansion and financial conservatism contrasts with softer freight demand and capacity imbalances that have led analysts to trim earnings expectations. Now we’ll explore how analysts’ cautious earnings revisions, despite Landstar’s heavy haul and Mexico expansion, reshape the company’s...
NasdaqGS:BMBL
NasdaqGS:BMBLInteractive Media and Services

Bumble (BMBL) Is Up 23.2% After AI-Led Bumble 2.0 Reveal And Upbeat 2026 Revenue Guidance

In March 2026, Bumble reported fourth-quarter 2025 results that exceeded revenue and earnings expectations, issued first-quarter 2026 revenue guidance of US$209 million to US$213 million (including US$171 million to US$174 million from the Bumble app), and highlighted stronger profitability despite fewer paying users. The company also unveiled an AI-powered overhaul, including its Bee model, the Dates assistant and the upcoming Bumble 2.0 cloud-native platform, aiming to improve user...
NYSE:AMTM
NYSE:AMTMProfessional Services

Is It Time To Reassess Amentum Holdings (AMTM) After The Recent Share Price Pullback

If you are wondering whether Amentum Holdings at US$27.90 is offering fair value or an opportunity, you are not alone in asking what the current price really reflects. The stock has seen a mixed return profile, with a 7% decline over the last week and an 8.2% decline over the last month, while still sitting on a 55.9% return over the past year and an 8.5% decline year to date. Recent news coverage around Amentum has focused on its position in the commercial services space and how investors...
NYSE:CCS
NYSE:CCSConsumer Durables

Century Communities Expands With Denver Luxury Rental Project The Stevie

Century Communities' multifamily division, Century Living, has acquired a shovel-ready site in Denver's LoHi neighborhood for a luxury apartment project called The Stevie. Groundbreaking is set to begin imminently, with leasing currently projected to start in 2028. The Stevie represents an expansion for NYSE:CCS further into high-end multifamily development in a central Denver location. Century Communities, listed on the NYSE under ticker CCS, is primarily known for building single-family...
NasdaqGS:QRVO
NasdaqGS:QRVOSemiconductor

Will Strong High Performance Analog Results and Segment Growth Change Qorvo's (QRVO) Narrative

Earlier this week, Qorvo reported an exceptional quarter with revenue up 8.4% year on year, beating analyst expectations for earnings per share and adjusted operating income, as all operating segments grew, led by automotive components, consumer and enterprise Wi‑Fi, base stations, and power management. Management also flagged an expected seasonal dip tied to its largest customer and the ongoing resizing of its Android business, while emphasizing continued strength in its High Performance...
NYSE:WMK
NYSE:WMKConsumer Retailing

Weis Markets (WMK) Margin Compression To 1.9% TTM Tests Defensive Grocer Narratives

Weis Markets (WMK) has wrapped up FY 2025 with fourth quarter revenue of US$1.3b, basic EPS of US$1.11 and net income of US$28.5m, setting the tone for how investors will read the latest set of numbers. Over recent quarters, revenue has ranged from US$1.20b in Q1 2025 to US$1.30b in Q4 2025, while basic EPS has moved between US$0.74 and US$1.11 over the same period, giving you a clear view of how sales and earnings have tracked through the year. With trailing twelve month net profit margin...
NasdaqGM:FIVN
NasdaqGM:FIVNSoftware

Legal Review Of Five9 Leadership Puts Governance And AI Ambitions In Focus

A law firm has launched an investigation into Five9's officers and directors over potential breaches of fiduciary duty to shareholders of NasdaqGM:FIVN. The probe focuses on whether management may have failed to act in shareholders' best interests, which could raise corporate governance concerns. This legal review has not been widely reported yet, making it a fresh development for existing and prospective investors. Five9, listed on NasdaqGM:FIVN, provides cloud contact center software used...
NasdaqGS:SBRA
NasdaqGS:SBRAHealth Care REITs

Is Sabra Health Care REIT (SBRA) Still Attractive After Strong Multi‑Year Share Price Gains

If you are wondering whether Sabra Health Care REIT is still reasonably priced at around US$20.62, you are not alone. The stock's recent performance has put valuation front and center. The share price shows returns of 1.0% over 7 days, 5.2% over 30 days, 7.7% year to date, 27.1% over 1 year and 73.5% over 5 years, which naturally raises questions about what is already baked into the price. Recent coverage has focused on Sabra as a healthcare focused REIT, with investors paying close...
NasdaqGS:WLTH
NasdaqGS:WLTHCapital Markets

Wealthfront Suit Raises Questions On IPO Disclosures And Valuation Gap

Wealthfront (NasdaqGS:WLTH) is under investigation in a securities class action focused on alleged issues in its IPO disclosures. The inquiry follows the company’s first quarterly report as a public firm, which was followed by a decline in the share price. Substantial net deposit outflows and questions around its new home lending business and ownership structure are central to investor concerns. Investors who experienced losses are assessing potential legal remedies tied to the IPO and...